Bezuclastinib

Name: Bezuclastinib in Gastrointestinal stromal tumor: Generic, brand name and therapeutic class of product
Published: 2026-09-14T15:39:06-04:00

Gastrointestinal stromal tumor

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted April 2026
Launch: Anticipated in the second half of 2026
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Generic, brand name and therapeutic class of product

2 evidence topics · 2 sources

Manufacturer: Cogent Biosciences

“Sponsor: Cogent Biosciences, Inc.” (opens the source at this quote in a new tab)

Product names and molecular targets

“Bezuclastinib (CGT9486, formerly PLX9486) is an investigational TKI that inhibits mutations in KIT exons 9, 11, 17, and 18.” (opens the source at this quote in a new tab)